Literature DB >> 19436942

Interferon-alpha-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathway.

Azusa Matsumoto1, Tatsuki Ichikawa, Kazuhiko Nakao, Hisamitsu Miyaaki, Kumi Hirano, Masumi Fujimito, Motohisa Akiyama, Satoshi Miuma, Eisuke Ozawa, Hidetaka Shibata, Shigeyuki Takeshita, Hironori Yamasaki, Masanori Ikeda, Nobuyuki Kato, Katsumi Eguchi.   

Abstract

OBJECT: The interferon-induced Jak-STAT signal alone is not sufficient to explain all the biological effects of IFN. The PI3-K pathways have emerged as a critical additional component of IFN-induced signaling. This study attempted to clarify that relationship between IFN-induced PI3-K-Akt-mTOR activity and anti-viral action. RESULT: When the human normal hepatocyte derived cell line was treated with rapamycin (rapa) before accretion of IFN-alpha, tyrosine phosphorylation of STAT-1 was diminished. Pretreatment of rapa had an inhibitory effect on the IFN-alpha-induced expression of PKR and p48 in a dose dependent manner. Rapa inhibited the IFN-alpha inducible IFN-stimulated regulatory element luciferase activity in a dose-dependent manner. However, wortmannin, LY294002 and Akt inhibitor did not influence IFN-alpha inducible luciferase activity. To examine the effect of PI3-K-Akt-mTOR on the anti-HCV action of IFN-alpha, the full-length HCV replication system, OR6 cells were used. The pretreatment of rapa attenuated its anti-HCV replication effect in comparison to IFN-alpha alone, whereas the pretreatment with PI3-K inhibitors, wortmannin and LY294002 and Akt inhibitor did not influence IFN-induced anti-HCV replication.
CONCLUSION: IFN-induced mTOR activity, independent of PI3K and Akt, is the critical factor for its anti-HCV activity. Jak independent mTOR activity involved STAT-1 phosphorylation and nuclear location, and then PKR is expressed in hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19436942     DOI: 10.1007/s00535-009-0075-1

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  33 in total

1.  Roles of phosphatidylinositol 3-kinase in interferon-gamma-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression.

Authors:  H Nguyen; C V Ramana; J Bayes; G R Stark
Journal:  J Biol Chem       Date:  2001-07-03       Impact factor: 5.157

2.  The production of IL-1 receptor antagonist in IFN-beta-stimulated human monocytes depends on the activation of phosphatidylinositol 3-kinase but not of STAT1.

Authors:  Nicolas Molnarfi; Nevila Hyka-Nouspikel; Lyssia Gruaz; Jean-Michel Dayer; Danielle Burger
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

Review 3.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.

Authors:  Jeffrey A Engelman; Ji Luo; Lewis C Cantley
Journal:  Nat Rev Genet       Date:  2006-08       Impact factor: 53.242

4.  p21-activated kinase 1 is activated through the mammalian target of rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in human hepatoma cells.

Authors:  Hisashi Ishida; Kui Li; Minkyung Yi; Stanley M Lemon
Journal:  J Biol Chem       Date:  2007-01-25       Impact factor: 5.157

5.  Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C.

Authors:  Ying Huang; Jordan J Feld; Ronda K Sapp; Santosh Nanda; Jiing-Huey Lin; Lawrence M Blatt; Michael W Fried; Krishna Murthy; T Jake Liang
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

6.  Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system.

Authors:  Masanori Ikeda; Ken-Ichi Abe; Hiromichi Dansako; Takashi Nakamura; Kazuhito Naka; Nobuyuki Kato
Journal:  Biochem Biophys Res Commun       Date:  2005-04-22       Impact factor: 3.575

7.  Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.

Authors:  Ryan J O Dowling; Mahvash Zakikhani; I George Fantus; Michael Pollak; Nahum Sonenberg
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

8.  Involvement of IL-1beta and IL-10 in IFN-alpha-mediated antiviral gene induction in human hepatoma cells.

Authors:  Tatsuki Ichikawa; Kazuhiko Nakao; Keisuke Nakata; Mayumi Yamashita; Keisuke Hamasaki; Masaya Shigeno; Seigou Abiru; Hiroki Ishikawa; Nobuko Ishii; Katsumi Eguchi
Journal:  Biochem Biophys Res Commun       Date:  2002-06-07       Impact factor: 3.575

9.  HCV NS5A inhibits interferon-alpha signaling through suppression of STAT1 phosphorylation in hepatocyte-derived cell lines.

Authors:  Keng-Hsin Lan; Keng-Li Lan; Wei-Ping Lee; Meei-Ling Sheu; Ming-Yuan Chen; Yung-Lu Lee; Sang-Hue Yen; Full-Young Chang; Shou-Dong Lee
Journal:  J Hepatol       Date:  2006-12-14       Impact factor: 25.083

10.  Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication.

Authors:  Chunfu Wang; Jill Pflugheber; Rhea Sumpter; Donald L Sodora; Daniel Hui; Ganes C Sen; Michael Gale
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

View more
  16 in total

1.  IL-29 and IFN-α regulate the expression of MxA, 2',5'-OAS and PKR genes in association with the activation of Raf-MEK-ERK and PI3K-AKT signal pathways in HepG2.2.15 cells.

Authors:  Yu Chai; Hai-Liang Huang; Dao-Jun Hu; Xin Luo; Qian-Shan Tao; Xiao-Ling Zhang; Sheng-Quan Zhang
Journal:  Mol Biol Rep       Date:  2010-03-23       Impact factor: 2.316

2.  Beta interferon regulation of glucose metabolism is PI3K/Akt dependent and important for antiviral activity against coxsackievirus B3.

Authors:  J D Burke; L C Platanias; E N Fish
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

3.  Geranylgeranylacetone has anti-hepatitis C virus activity via activation of mTOR in human hepatoma cells.

Authors:  Shigeyuki Takeshita; Tatsuki Ichikawa; Naota Taura; Hisamitsu Miyaaki; Toshihisa Matsuzaki; Masashi Otani; Toru Muraoka; Motohisa Akiyama; Satoshi Miuma; Eisuke Ozawa; Masanori Ikeda; Nobuyuki Kato; Hajime Isomoto; Fuminao Takeshima; Kazuhiko Nakao
Journal:  J Gastroenterol       Date:  2011-10-25       Impact factor: 7.527

Review 4.  Potential use of rapamycin in HIV infection.

Authors:  Marco Donia; James A McCubrey; Klaus Bendtzen; Ferdinando Nicoletti
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

5.  Pegylated IFN-α suppresses hepatitis C virus by promoting the DAPK-mTOR pathway.

Authors:  Wei-Liang Liu; Hung-Chih Yang; Ching-Sheng Hsu; Chih-Chiang Wang; Tzu-San Wang; Jia-Horng Kao; Ding-Shinn Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-06       Impact factor: 11.205

Review 6.  Regulation of interferon-dependent mRNA translation of target genes.

Authors:  Barbara Kroczynska; Swarna Mehrotra; Ahmet Dirim Arslan; Surinder Kaur; Leonidas C Platanias
Journal:  J Interferon Cytokine Res       Date:  2014-02-21       Impact factor: 2.607

Review 7.  Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes.

Authors:  Eleanor N Fish; Leonidas C Platanias
Journal:  Mol Cancer Res       Date:  2014-09-12       Impact factor: 5.852

8.  Modulation of PI3K-LXRα-dependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin.

Authors:  Sandra Pisonero-Vaquero; María V García-Mediavilla; Francisco Jorquera; Pedro L Majano; Marta Benet; Ramiro Jover; Javier González-Gallego; Sonia Sánchez-Campos
Journal:  Lab Invest       Date:  2014-02-03       Impact factor: 5.662

Review 9.  Hepatitis C virus reactivation in cancer patients in the era of targeted therapies.

Authors:  Ozan Yazici; Mehmet Ali Nahit Sendur; Sercan Aksoy
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

10.  Lewis y antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cells through the PI3K/Akt signaling pathway.

Authors:  Juanjuan Liu; Bei Lin; Yingying Hao; Yue Qi; Liancheng Zhu; Feifei Li; Dawo Liu; Jianping Cong; Shulan Zhang; Masao Iwamori
Journal:  J Exp Clin Cancer Res       Date:  2009-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.